Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
about
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myelomaMonoclonal antibodies targeting CD38 in hematological malignancies and beyondDaratumumab: First Global Approval.Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.An update on the role of daratumumab in the treatment of multiple myeloma.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Harnessing benefit from targeting tumor associated carbohydrate antigens.Immunotherapies targeting CD38 in Multiple Myeloma.The multi-faceted potential of CD38 antibody targeting in multiple myeloma.Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationEmerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple MyelomaSepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.Triplet vs. doublet drug regimens for managing multiple myeloma.High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistanceLenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patientsCorrelation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
P2860
Q26745919-5FB7087F-1563-4E6E-A9B5-EDA162ADECACQ26766718-70919720-2685-4B03-A49F-E3F659C6EEDAQ34507354-7B5B7C06-DEE8-48B1-8B0E-D43A2323BEE9Q36060298-530F309C-1EF5-4197-A9F0-1D4BE07704B5Q37035836-0400DCDE-F8F9-496A-8A88-129EB8437E50Q37517482-9C129B2F-D286-4486-9057-5C3C93A1C6DAQ38737970-82F61162-DB7B-4B1F-AD5B-E166D6976232Q38745915-B2267722-DD9C-4A68-AA6F-E27912547C34Q38775700-7F412990-AC0A-4EA3-BE96-B5C22DF2CDC5Q38817467-75EAE8DB-3037-4686-AF2F-7820B69D3188Q38820002-2B56656D-7243-43BF-AF2F-26BBE25F66C6Q38824538-0FEAF45E-5BCD-4133-959C-8B1569D70DE2Q39032812-19BA56FB-480D-4239-9EB5-B9C914B35CB7Q39045031-6BF62CE6-E242-4E1F-B98B-B403DF0D3B7AQ39200031-87917770-4CC1-41FC-8B36-453E02BE077DQ41345636-9BE070D1-83E8-409E-A8CA-F12AAF59599CQ41370609-7C4E244B-1018-40F1-8801-93B9D1FD150EQ42391580-66C4AD11-C243-4D1A-BB55-4971E773B821Q46754093-E7009C2E-4D8B-4F1E-BF1F-BE4B7FA3AC58Q47203479-02A8607A-81B5-442B-9EBD-102F40BF28CDQ47614728-D2361EF7-34EA-4B69-AC8E-0F1F055CEB7FQ47660573-8CFB019D-C36C-4A2F-A5F2-17FCE7D67CADQ47770089-33D1797D-16D5-460A-B2A9-47FC187926CBQ48987219-581F6C35-E40D-4EF9-A1F2-80D40B46544BQ52676274-56E25FBB-AB68-4EF9-8DDC-F0FFE1E5300EQ57191729-B4EB6A80-EA28-4CED-85DB-1FB33A222A24Q58552961-20CF0DD7-479A-405E-A0B2-758E9BBE0B43Q58800038-404EA522-1D34-4295-B10F-EFC55C9FACEF
P2860
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Preclinical Evidence for the T ...... o Lenalidomide and Bortezomib.
@en
type
label
Preclinical Evidence for the T ...... o Lenalidomide and Bortezomib.
@en
prefLabel
Preclinical Evidence for the T ...... o Lenalidomide and Bortezomib.
@en
P2093
P1476
Preclinical Evidence for the T ...... o Lenalidomide and Bortezomib.
@en
P2093
Anton C M Martens
Berris van Kessel
Henk M Lokhorst
Inger S Nijhof
Jeroen J L van Bueren
Joost Bakker
Niels W C J van de Donk
Regina de Jong-Korlaar
Tuna Mutis
Willy A Noort
P304
P356
10.1158/1078-0432.CCR-14-1813
P407
P577
2014-11-14T00:00:00Z